233 related articles for article (PubMed ID: 36608132)
21. E3 ubiquitin-protein ligase TRIM21-mediated lysine capture by UBE2E1 reveals substrate-targeting mode of a ubiquitin-conjugating E2.
Anandapadamanaban M; Kyriakidis NC; Csizmók V; Wallenhammar A; Espinosa AC; Ahlner A; Round AR; Trewhella J; Moche M; Wahren-Herlenius M; Sunnerhagen M
J Biol Chem; 2019 Jul; 294(30):11404-11419. PubMed ID: 31160341
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
[TBL] [Abstract][Full Text] [Related]
23. CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection.
Wennerberg E; Spada S; Rudqvist NP; Lhuillier C; Gruber S; Chen Q; Zhang F; Zhou XK; Gross SS; Formenti SC; Demaria S
Cancer Immunol Res; 2020 Apr; 8(4):465-478. PubMed ID: 32047024
[TBL] [Abstract][Full Text] [Related]
24. Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer.
Jin F; Qi J; Liu D; You Y; Shu G; Du Y; Wang J; Xu X; Ying X; Ji J; Du Y
J Control Release; 2021 Sep; 337():90-104. PubMed ID: 34274385
[TBL] [Abstract][Full Text] [Related]
25. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
26. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
[TBL] [Abstract][Full Text] [Related]
27. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
28. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
29. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
[TBL] [Abstract][Full Text] [Related]
30. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
31. The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment.
Chen X; Cao M; Wang P; Chu S; Li M; Hou P; Zheng J; Li Z; Bai J
Front Immunol; 2022; 13():968755. PubMed ID: 36159815
[TBL] [Abstract][Full Text] [Related]
32. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
33. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
34. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation.
Zhu L; Kuang X; Zhang G; Liang L; Liu D; Hu B; Xie Z; Li H; Liu H; Ye M; Chen X; Liu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577504
[TBL] [Abstract][Full Text] [Related]
35. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
[TBL] [Abstract][Full Text] [Related]
36. Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers.
Tang K; Zhang J; Cao H; Xiao G; Wang Z; Zhang X; Zhang N; Wu W; Zhang H; Wang Q; Xu H; Cheng Q
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428755
[TBL] [Abstract][Full Text] [Related]
37. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
38. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21.
Itou J; Li W; Ito S; Tanaka S; Matsumoto Y; Sato F; Toi M
J Biol Chem; 2018 Apr; 293(17):6556-6564. PubMed ID: 29511085
[TBL] [Abstract][Full Text] [Related]
39. A Interacting Model: How TRIM21 Orchestrates with Proteins in Intracellular Immunity.
Huang Y; Gao X; He QY; Liu W
Small Methods; 2024 Jan; 8(1):e2301142. PubMed ID: 37922533
[TBL] [Abstract][Full Text] [Related]
40. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB; Phan LH; Villarreal OE; Bowser JL
Front Immunol; 2020; 11():508. PubMed ID: 32351498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
